FindTrial
Sign In

Comparison of Conditioning Regimens in Alternative Donor Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia

Comparison of Bu/Cy/ATG versus Flu/Cy/ATG Conditioning Regimens in Alternative Donor Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia: A Retrospective Observational Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600128918
Enrollment
Unknown
Registered
2026-07-28
Start date
2026-08-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe aplastic anemia

Interventions

Bu/Cy/ATG group:None
Flu/Cy/ATG group:None

Sponsors

Zhejiang Provincial Hospital of TCM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
8 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Disease diagnosis: Meets the diagnostic criteria for severe aplastic anemia (SAA), e.g., Camitta criteria; 2.Transplant type: Received allogeneic hematopoietic stem cell transplantation from an alternative donor, including haploidentical donor or unrelated donor; 3.Conditioning regimen: The conditioning regimen is either Bu/Cy/ATG (busulfan + cyclophosphamide + anti-thymocyte globulin) or Flu/Cy/ATG (fludarabine + cyclophosphamide + anti-thymocyte globulin); 4.Age: =8 years and =60 years, both genders; 5.Data completeness: Complete clinical data available to retrieve primary outcome measures (overall survival, failure-free survival, etc.);

Exclusion criteria

Exclusion criteria: 1.Donor type not eligible: Received transplantation from an HLA-identical sibling donor; 2.Non-target conditioning regimen: Conditioning regimen other than Bu/Cy/ATG or Flu/Cy/ATG; 3.Prior transplantation: History of previous hematopoietic stem cell transplantation (second transplant); 4.Severe missing data: Key variables (e.g., survival outcome, engraftment status, GVHD grade) are missing, making primary analysis impossible; 5.Others: Any condition that, in the investigator’s opinion, may interfere with the evaluation of study outcomes;

Design outcomes

Primary

MeasureTime frame
Overall Survival;Event?Free Survival;—

Secondary

MeasureTime frame
CMV Viremia;Adverse Event (AE) Incidence;Time to Platelet Engraftment;Time to Neutrophil Engraftment;Chronic Graft-versus-Host Disease (cGVHD);Transplant?Related Mortality (TRM);Neutrophil Engraftment Rate;Acute Graft-versus-Host Disease (aGVHD);Graft Failure (Primary/Secondary);Platelet Engraftment Rate;EBV Viremia and Post-Transplant Lymphoproliferative Disease (PTLD);—

Countries

China

Contacts

Public ContactXianfu Sheng

Zhejiang Provincial Hospital of TCM

648268322@qq.com+86 571 86008701

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026